Implementation of mass pharmacogenetic testing <i>: Dihydropyrimidine dehydrogenase</i> testing prior to fluoropyrimidine treatment for patients
Through multiprofessional, national collaboration, this is the first report studying the large-scale rollout of a nationally commissioned pharmacogenetic test. Whilst DPYD testing has been successfully implemented, there is a need to standardize and improve end-to-end turnaround times. This has led to the development of a best practice pathway. Critically, GMSAs must build on this implementation to deliver its priorities, in supporting equitable access to future pharmacogenomic testing across a wider cohort of therapies.
Authors
- Jessica Keen (ORCID: https://orcid.org/0009-0009-7708-8534)
- Munir Pirmohamed (ORCID: https://orcid.org/0000-0002-7534-7266)
- Anna Kim (ORCID: https://orcid.org/0000-0002-2953-8811)
- Nisha Shaunak (ORCID: https://orcid.org/0009-0009-8394-9257)
- William G. Newman (ORCID: https://orcid.org/0000-0002-6382-4678)
- Paul J. Ross (ORCID: https://orcid.org/0000-0002-2390-1886)
Institutions
- University of Liverpool (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- University of Manchester (GB)
- Manchester University NHS Foundation Trust (GB)
- South East Health Technologies Alliance (GB)
- Genomics (United Kingdom) (GB)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-04-27
- DOI
- https://doi.org/10.1002/bcp.70057
- Citations
- 3
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- National Institute for Health and Care Research
- Manchester Biomedical Research Centre